Safe Cosmetics and Personal Care Products Act of 2019
Legislative Progress
Introduced
September 12, 2019
Latest Action
September 13, 2019
Primary Sponsor
Janice D. SchakowskyDemocratic(IL)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
51pct
1d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Safe Cosmetics and Personal Care Products Act of 2019 This bill expands the Food and Drug Administration's authority to regulate cosmetics, including with respect to safety standards, product recalls, and product testing. The bill also generally prohibits the use of animal testing for the purpose of developing cosmetics.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (11)
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2020 · fourth_quarter · Consumer Issues/Safety/Products
We worked on H.R. 4296 the Safe Cosmetics and Personal Care Products Act to ensure that cosmetics and personal care products that targeted people of color were included in the bill. We also worked to make sure that funds were set aside to support research on the health effects of chemicals that are most regularly found in the cosmetic and personal care products targeting people of color. S.4617 - Environmental Justice Legacy Pollution Cleanup Act of 2020 H.R.5986 - Environmental Justice For All Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Consumer Issues/Safety/Products
We worked on H.R. 4296 the Safe Cosmetics and Personal Care Products Act to ensure that cosmetics and personal care products that targeted people of color were included in the bill. We also worked to make sure that funds were set aside to support research on the health effects of chemicals that are most regularly found in the cosmetic and personal care products targeting people of color. S.4617 - Environmental Justice Legacy Pollution Cleanup Act of 2020 H.R.5986 - Environmental Justice For All Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Consumer Issues/Safety/Products
We worked on H.R. 4296 the Safe Cosmetics and Personal Care Products Act to ensure that cosmetics and personal care products that targeted people of color were included in the bill. We also worked to make sure that funds were set aside to support research on the health effects of chemicals that are most regularly found in the cosmetic and personal care products targeting people of color. S.4617 - Environmental Justice Legacy Pollution Cleanup Act of 2020 H.R.5986 - Environmental Justice For All Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials - Issues related to 340B - S.4613, The Contact Lens Rule Modernization Act, regarding all provisions - H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications -H.R.133 - Consolidated Appropriations Act, 2021, including legislation regarding average sales price (ASP) reporting requirements for certain hyaluronic acid (HA) products that are classified as devices, but reimbursed as drugs under Medicare Part B
2020 · fourth_quarter · Consumer Issues/Safety/Products
-S.726:Personal Care Products Safety Act -Ingredients in diapers and feminine hygiene products -Liquid laundry pac ATSM/Pods product safety -Infrastructure -H.R.4296:Safe Cosmetics and Personal Care Products Act of 2019 -H.R.269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client expense: $661,421 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
| Democratic |
| IN |
| Ayanna Pressley | Democratic | MA |
| Barbara Lee | Democratic | CA |
| Bennie G. Thompson | Democratic | MS |
| Betty McCollum | Democratic | MN |
| Chellie Pingree | Democratic | ME |
| Debbie Mucarsel-Powell | Democratic | FL |
| Debbie Wasserman Schultz | Democratic | FL |
| Diana DeGette | Democratic | CO |
| Doris O. Matsui | Democratic | CA |
| Earl Blumenauer | Democratic | OR |
| Elaine G. Luria | Democratic | VA |
| Eleanor Holmes Norton | Democratic | DC |
| Grace F. Napolitano | Democratic | CA |
| Grace Meng | Democratic | NY |
| Harley Rouda | Democratic | CA |
| Jackie Speier | Democratic | CA |
| Jamie Raskin | Democratic | MD |
| Jared Huffman | Democratic | CA |
| Jerrold Nadler | Democratic | NY |
| Joseph D. Morelle | Democratic | NY |
| Joyce Beatty | Democratic | OH |
| Judy Chu | Democratic | CA |
| Mark Pocan | Democratic | WI |
| Nydia M. Velázquez | Democratic | NY |
| Paul Tonko | Democratic | NY |
| Pramila Jayapal | Democratic | WA |
| Rashida Tlaib | Democratic | MI |
| Raúl M. Grijalva | Democratic | AZ |
| Ro Khanna | Democratic | CA |
| Rosa L. DeLauro | Democratic | CT |
| Sean Patrick Maloney | Democratic | NY |
| Sheila Jackson Lee | Democratic | TX |
| Ted Lieu | Democratic | CA |
| Theodore E. Deutch | Democratic | FL |
| Tom Malinowski | Democratic | NJ |
| Yvette D. Clarke | Democratic | NY |
| Zoe Lofgren | Democratic | CA |
Client expense: $1,450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · fourth_quarter · Chemicals/Chemical Industry
Proposals to reform FDA authority and personal care products regulatory system. Specifically, H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; and H.R. 5017 - Natural Cosmetics Act.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Consumer Issues/Safety/Products
Proposals to reform FDA authority and personal care products regulatory system. Specifically, H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; and H.R. 5017 - Natural Cosmetics Act.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Environment/Superfund
Proposals to reform FDA authority and personal care products regulatory system. Specifically, H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; and H.R. 5017 - Natural Cosmetics Act.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Proposals to reform FDA authority and personal care products regulatory system. Specifically, H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; and H.R. 5017 - Natural Cosmetics Act.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Consumer Issues/Safety/Products
H.R. 1423, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 610, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 608, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education. H.R. 1430, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education S. 630, Arbitration Fairness for Consumers Act, a bill to amend the Consumer Financial Protection Act of 2010 with respect to arbitration. H.R. 1443, Ending Forced Arbitration of Sexual Harassment act of 2019, bill to amend title 9 of the United States Code with respect to arbitration, prohibiting the use of forced arbitration in cases of sexual harassment, assault, discrimination. S. 635, A bill to restore statutory rights to the people of the United States from forced arbitration. S. 620, Safety Over Arbitration, a bill to amend title 9, United States Code, with respect to arbitration. S. 726, Personal Care Products Safety Act, to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, specifically regarding preemption and immunity provisions. H.R. 2750, Justice for Servicemembers Act, prohibiting the use of forced arbitration against members of the armed forces. H.R. 2749/ S. 1491 Restoring Justice for Workers Act, prohibiting the use of forced arbitration in employment disputes. H.R. 3764, Justice for Student Borrowers Act, prohibiting the use of forced arbitration in student loan agreements. S. 766, PROTECT Asbestos Victims Act of 2019. H.R. 1603/ S. 717, Alan Reinstein Ban Asbestos Now Act of 2019. H.R. 1816, Children's Product Warning Label Act of 2019. Dingell and Cicilline amendments to H.R. 2500, National Defense Authorization Act, regarding PFAS CERCLA designation (Dingell), and prohibiting the use of forced arbitration in SCRA claims (Cicilline). H.R. 5216/ S. 2943, Quality Care for Nursing Home Residents Act of 2019. H.R. 5326, Fairness in Nursing Home Arbitration Act. H.R. 4544, Ensuring Fair Legal Recourse for Private Student Loan Borrowers Act. H.R. 5279, Cosmetic Safety Enhancement Act of 2019. H.R. 5017, Natural Cosmetics Act. H.R. 535, PFAS Action of 2019. S. 2838, A bill to amend the Ted Stevens Olympic Amateur Sports Act to improve transparency of the United States Center for Safe Sport, to provide grant accountability, and to protect victims of abuse from retaliation, and for other purposes. H.R. 4982, Health Care Workforce Protection Act of 2019. S. 3372, Health Care Workforce Protection Act. H.R. 748, CARES Act, with specific regard to immunity provisions. S. 3548, CARES Act, with specific regard to immunity provisions. H.R. 6201, Families First Coronavirus Response Act, with specific regard to immunity provisions. H.R. 6379, Take Responsibility for Workers and Families Act, with specific regard to immunity provisions. H.R. 6101/ S. 3400, Ending Passenger Rail Forced Arbitration. H.R. 6058, SHOP SAFE Act of 2020. H.R. 6044, Accurate Labels Act. H.R. 6395/ S. 4049, National Defense Authorization Act (NDAA), with specific regard to servicemember forced arbitration amendments. H.R. 7940, Protect America's Children from Toxic Pesticides Act. S. 4317, Safe to Work Act. S. 178, Delivering Immediate Relief to American Families, Schools, and Small Businesses Act. H.R. 7528, Get America Back to Work Act. H.R. 8237, Protecting the Employment Rights of Service Members. H.R. 133, Consolidated Appropriations Act, 2021. Portman/ Cornyn COVID Relief Draft Proposal. Draft Ending Mandatory Arbitration for Sexual Assault Claims Act. Draft legislation regarding additions to the PREP Act. General lobbying with regard to asbestos in talc and related liability issues. General lobbying with regard to asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to preemption of state causes of action. General lobbying with regard to PFAS liability issues. General lobbying with regard to evidence availability in pipeline safety legislation. General lobbying with regard to immunity provisions and liability frameworks in COVID-19 legislation. General lobbying with regard to nursing home COVID-19 liablity.
Client expense: $1,110,000 · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
2020 · fourth_quarter · Manufacturing
H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain HR 8837 -- Continuing Appropriations Act, 2021 and Other Extensions Act H.R.133 - Consolidated Appropriations Act, 2021
Client expense: $146,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
2020 · fourth_quarter · Consumer Issues/Safety/Products
Monitoring FDA regulation of cosmetics and Consumer Product Safety issues. Monitor data breach notification, cyber-security and digital privacy proposals. H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 4296 - Safe Cosmetics and Personal Care Products Act of 2019. S. 726 - Personal Care Products Safety Act. Infrastructure.
Client expense: Not reported · Firm income: $50,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2020 · third_quarter · Consumer Issues/Safety/Products
We worked on H.R. 4296 the Safe Cosmetics and Personal Care Products Act to ensure that cosmetics and personal care products that targeted people of color were included in the bill. We also worked to make sure that funds were set aside to support research on the health effects of chemicals that are most regularly found in the cosmetic and personal care products targeting people of color.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2020 · second_quarter · Consumer Issues/Safety/Products
We worked on H.R. 4296 the Safe Cosmetics and Personal Care Products Act to ensure that cosmetics and personal care products that targeted people of color were included in the bill. We also worked to make sure that funds were set aside to support research on the health effects of chemicals that are most regularly found in the cosmetic and personal care products targeting people of color.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2020 · third_quarter · Consumer Issues/Safety/Products
Monitoring FDA regulation of cosmetics and Consumer Product Safety issues. Monitor data breach notification, cyber-security and digital privacy proposals. H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 4296 - Safe Cosmetics and Personal Care Products Act of 2019. S. 726 - Personal Care Products Safety Act. Infrastructure.
Client expense: Not reported · Firm income: $50,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2020 · third_quarter · Consumer Issues/Safety/Products
H.R. 1423, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 610, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 608, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education. H.R. 1430, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education S. 630, Arbitration Fairness for Consumers Act, a bill to amend the Consumer Financial Protection Act of 2010 with respect to arbitration. H.R. 1443, Ending Forced Arbitration of Sexual Harassment act of 2019, bill to amend title 9 of the United States Code with respect to arbitration, prohibiting the use of forced arbitration in cases of sexual harassment, assault, discrimination. S. 635, A bill to restore statutory rights to the people of the United States from forced arbitration. S. 620, Safety Over Arbitration, a bill to amend title 9, United States Code, with respect to arbitration. S. 726, Personal Care Products Safety Act, to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, specifically regarding preemption and immunity provisions. H.R. 2750, Justice for Servicemembers Act, prohibiting the use of forced arbitration against members of the armed forces. H.R. 2749/ S. 1491 Restoring Justice for Workers Act, prohibiting the use of forced arbitration in employment disputes. H.R. 3764, Justice for Student Borrowers Act, prohibiting the use of forced arbitration in student loan agreements. S. 766, PROTECT Asbestos Victims Act of 2019. H.R. 1603/ S. 717, Alan Reinstein Ban Asbestos Now Act of 2019. H.R. 1816, Children's Product Warning Label Act of 2019. Dingell and Cicilline amendments to H.R. 2500, National Defense Authorization Act, regarding PFAS CERCLA designation (Dingell), and prohibiting the use of forced arbitration in SCRA claims (Cicilline). H.R. 5216/ S. 2943, Quality Care for Nursing Home Residents Act of 2019. H.R. 5326, Fairness in Nursing Home Arbitration Act. H.R. 4544, Ensuring Fair Legal Recourse for Private Student Loan Borrowers Act. H.R. 5279, Cosmetic Safety Enhancement Act of 2019. H.R. 5017, Natural Cosmetics Act. H.R. 535, PFAS Action of 2019. S. 2838, A bill to amend the Ted Stevens Olympic Amateur Sports Act to improve transparency of the United States Center for Safe Sport, to provide grant accountability, and to protect victims of abuse from retaliation, and for other purposes. H.R. 4982, Health Care Workforce Protection Act of 2019. S. 3372, Health Care Workforce Protection Act. H.R. 748, CARES Act, with specific regard to immunity provisions. S. 3548, CARES Act, with specific regard to immunity provisions. H.R. 6201, Families First Coronavirus Response Act, with specific regard to immunity provisions. H.R. 6379, Take Responsibility for Workers and Families Act, with specific regard to immunity provisions. H.R. 6101/ S. 3400, Ending Passenger Rail Forced Arbitration. H.R. 6058, SHOP SAFE Act of 2020. H.R. 6044, Accurate Labels Act. H.R. 6395/ S. 4049, National Defense Authorization Act (NDAA), with specific regard to servicemember forced arbitration amendments. H.R. 7940, Protect America's Children from Toxic Pesticides Act. S. 4317, Safe to Work Act. S. 178, Delivering Immediate Relief to American Families, Schools, and Small Businesses Act. H.R. 7528, Get America Back to Work Act. H.R. 8237, Protecting the Employment Rights of Service Members. Draft Ending Mandatory Arbitration for Sexual Assault Claims Act. Draft legislation regarding additions to the PREP Act. General lobbying with regard to asbestos in talc and related liability issues. General lobbying with regard to asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to preemption of state causes of action. General lobbying with regard to PFAS liability issues. General lobbying with regard to evidence availability in pipeline safety legislation. General lobbying with regard to immunity provisions in COVID-19 legislation. General lobbying with regard to nursing home COVID-19 liablity.
Client expense: $1,400,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
2020 · third_quarter · Consumer Issues/Safety/Products
Cosmetics Regulation S. 726 Personal Care Products Safety Act Consumer protection and product safety standards and regulations in cosmetic industry H.R. 4296 - Safe Cosmetics and Personal Care Products Act of 2019
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials - Issues related to 340B - S.4613, The Contact Lens Rule Modernization Act, regarding all provisions - H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications
Client expense: $860,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · third_quarter · Manufacturing
H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain HR 8837 -- Continuing Appropriations Act, 2021 and Other Extensions Act
Client expense: $140,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
2020 · first_quarter · Consumer Issues/Safety/Products
We worked on H.R. 4296 the Safe Cosmetics and Personal Care Products Act to ensure that cosmetics and personal care products that targeted people of color were included in the bill. We also worked to make sure that funds were set aside to support research on the health effects of chemicals that are most regularly found in the cosmetic and personal care products targeting people of color.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2020 · second_quarter · Consumer Issues/Safety/Products
Cosmetics Regulation S. 726 Personal Care Products Safety Act Consumer protection and product safety standards and regulations in cosmetic industry H.R. 4296 - Safe Cosmetics and Personal Care Products Act of 2019
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Consumer Issues/Safety/Products
Cosmetics Regulation S. 726 Personal Care Products Safety Act Consumer protection and product safety standards and regulations in cosmetic industry H.R. 4296 - Safe Cosmetics and Personal Care Products Act of 2019
Client expense: Not reported · Firm income: $10,000
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials
Client expense: $1,760,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · second_quarter · Consumer Issues/Safety/Products
H.R. 1423, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 610, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 608, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education. H.R. 1430, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education S. 630, Arbitration Fairness for Consumers Act, a bill to amend the Consumer Financial Protection Act of 2010 with respect to arbitration. H.R. 1443, Ending Forced Arbitration of Sexual Harassment act of 2019, bill to amend title 9 of the United States Code with respect to arbitration, prohibiting the use of forced arbitration in cases of sexual harassment, assault, discrimination. S. 635, A bill to restore statutory rights to the people of the United States from forced arbitration. S. 620, Safety Over Arbitration, a bill to amend title 9, United States Code, with respect to arbitration. S. 726, Personal Care Products Safety Act, to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, specifically regarding preemption and immunity provisions. H.R. 2750, Justice for Servicemembers Act, prohibiting the use of forced arbitration against members of the armed forces. H.R. 2749/ S. 1491 Restoring Justice for Workers Act, prohibiting the use of forced arbitration in employment disputes. H.R. 3764, Justice for Student Borrowers Act, prohibiting the use of forced arbitration in student loan agreements. S. 766, PROTECT Asbestos Victims Act of 2019. H.R. 1603/ S. 717, Alan Reinstein Ban Asbestos Now Act of 2019. H.R. 1816, Children's Product Warning Label Act of 2019. Dingell and Cicilline amendments to H.R. 2500, National Defense Authorization Act, regarding PFAS CERCLA designation (Dingell), and prohibiting the use of forced arbitration in SCRA claims (Cicilline). H.R. 5216/ S. 2943, Quality Care for Nursing Home Residents Act of 2019. H.R. 5326, Fairness in Nursing Home Arbitration Act. H.R. 4544, Ensuring Fair Legal Recourse for Private Student Loan Borrowers Act. H.R. 5279, Cosmetic Safety Enhancement Act of 2019. H.R. 5017, Natural Cosmetics Act. H.R. 535, PFAS Action of 2019. S. 2838, A bill to amend the Ted Stevens Olympic Amateur Sports Act to improve transparency of the United States Center for Safe Sport, to provide grant accountability, and to protect victims of abuse from retaliation, and for other purposes. H.R. 4982, Health Care Workforce Protection Act of 2019. S. 3372, Health Care Workforce Protection Act. H.R. 748, CARES Act, with specific regard to immunity provisions. S. 3548, CARES Act, with specific regard to immunity provisions. H.R. 6201, Families First Coronavirus Response Act, with specific regard to immunity provisions. H.R. 6379, Take Responsibility for Workers and Families Act, with specific regard to immunity provisions. H.R. 6101/ S. 3400, Ending Passenger Rail Forced Arbitration. H.R. 6058, SHOP SAFE Act of 2020. H.R. 6044, Accurate Labels Act. H.R. 6395/ S. 4049, National Defense Authorization Act (NDAA), with specific regard to servicemember forced arbitration amendments. Draft legislation regarding additions to the PREP Act. General lobbying with regard to asbestos in talc and related liability issues. General lobbying with regard to asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to preemption of state causes of action. General lobbying with regard to PFAS liability issues. General lobbying with regard to evidence availability in pipeline safety legislation. General lobbying with regard to immunity provisions in COVID-19 legislation. General lobbying with regard to nursing home COVID-19 liablity.
Client expense: $1,350,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Consumer Issues/Safety/Products
Monitoring FDA regulation of cosmetics and Consumer Product Safety issues. Monitor data breach notification, cyber-security and digital privacy proposals. H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 4296 - Safe Cosmetics and Personal Care Products Act of 2019. S. 726 - Personal Care Products Safety Act. Infrastructure.
Client expense: Not reported · Firm income: $50,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2020 · second_quarter · Health Issues
HOUSE AND SENATE APPROPRIATIONS Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) CURRENT LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports reforming and strengthening the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; H.R. 5017 - Natural Cosmetics Act; and additional proposals that would impact the regulation of cosmetics and personal care products. Breast Cancer Prevention Partners visits Congressional offices to oppose H.R. 6044 - Accurate Labels Act, and other legislative proposals that seek to undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products. Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of pesticides and personal care products. These include H.R. 5986 - Environmental Justice for All Act and S.2236 - Environmental Justice Act of 2019. FUTURE LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A (BPA). Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS). Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions. Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural". REGULATION AND LEGISLATIVE INTENT: P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: Not reported
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · second_quarter · Environment/Superfund
HOUSE AND SENATE APPROPRIATIONS Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) CURRENT LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports reforming and strengthening the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; H.R. 5017 - Natural Cosmetics Act; and additional proposals that would impact the regulation of cosmetics and personal care products. Breast Cancer Prevention Partners visits Congressional offices to oppose H.R. 6044 - Accurate Labels Act, and other legislative proposals that seek to undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products. Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of pesticides and personal care products. These include H.R. 5986 - Environmental Justice for All Act and S.2236 - Environmental Justice Act of 2019. FUTURE LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A (BPA). Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS). Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions. Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural". REGULATION AND LEGISLATIVE INTENT: P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: Not reported
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · second_quarter · Chemicals/Chemical Industry
HOUSE AND SENATE APPROPRIATIONS Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) CURRENT LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports reforming and strengthening the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; H.R. 5017 - Natural Cosmetics Act; and additional proposals that would impact the regulation of cosmetics and personal care products. Breast Cancer Prevention Partners visits Congressional offices to oppose H.R. 6044 - Accurate Labels Act, and other legislative proposals that seek to undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products. Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of pesticides and personal care products. These include H.R. 5986 - Environmental Justice for All Act and S.2236 - Environmental Justice Act of 2019. FUTURE LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A (BPA). Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS). Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions. Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural". REGULATION AND LEGISLATIVE INTENT: P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: Not reported
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · second_quarter · Consumer Issues/Safety/Products
HOUSE AND SENATE APPROPRIATIONS Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) CURRENT LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports reforming and strengthening the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; H.R. 5017 - Natural Cosmetics Act; and additional proposals that would impact the regulation of cosmetics and personal care products. Breast Cancer Prevention Partners visits Congressional offices to oppose H.R. 6044 - Accurate Labels Act, and other legislative proposals that seek to undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products. Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of pesticides and personal care products. These include H.R. 5986 - Environmental Justice for All Act and S.2236 - Environmental Justice Act of 2019. FUTURE LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A (BPA). Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS). Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions. Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural". REGULATION AND LEGISLATIVE INTENT: P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: Not reported
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · second_quarter · Torts
H.R. 1603: The Alan Reinstein Ban Asbestos Now Act of 2019 H.R. 4296: The "Safe Cosmetics and Personal Care Products Act of 2019" H.R. 5279: Cosmetic Safety Enhancement Act of 2019 S. 766: The PROTECT Asbestos Victims Act of 2019
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Manufacturing
H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain
Client expense: $128,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
2020 · first_quarter · Consumer Issues/Safety/Products
Cosmetics Regulation S. 726 Personal Care Products Safety Act Consumer protection and product safety standards and regulations in cosmetic industry H.R. 4296 - Safe Cosmetics and Personal Care Products Act of 2019
Client expense: Not reported · Firm income: $10,000
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Consumer Issues/Safety/Products
Monitoring FDA regulation of cosmetics and Consumer Product Safety issues. Monitor data breach notification, cyber-security and digital privacy proposals. H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 4296 - Safe Cosmetics and Personal Care Products Act of 2019. S. 726 - Personal Care Products Safety Act. Cosmetics reform, infrastructure.
Client expense: Not reported · Firm income: $50,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2020 · first_quarter · Consumer Issues/Safety/Products
H.R. 1423, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 610, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 608, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education. H.R. 1430, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education S. 630, Arbitration Fairness for Consumers Act, a bill to amend the Consumer Financial Protection Act of 2010 with respect to arbitration. H.R. 1443, Ending Forced Arbitration of Sexual Harassment act of 2019, bill to amend title 9 of the United States Code with respect to arbitration, prohibiting the use of forced arbitration in cases of sexual harassment, assault, discrimination. S. 635, A bill to restore statutory rights to the people of the United States from forced arbitration. S. 620, Safety Over Arbitration, a bill to amend title 9, United States Code, with respect to arbitration. S. 726, Personal Care Products Safety Act, to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, specifically regarding preemption and immunity provisions. H.R. 2750, Justice for Servicemembers Act, prohibiting the use of forced arbitration against members of the armed forces. H.R. 2749/ S. 1491 Restoring Justice for Workers Act, prohibiting the use of forced arbitration in employment disputes. H.R. 3764, Justice for Student Borrowers Act, prohibiting the use of forced arbitration in student loan agreements. S. 766, PROTECT Asbestos Victims Act of 2019. H.R. 1603/ S. 717, Alan Reinstein Ban Asbestos Now Act of 2019. H.R. 1816, Children's Product Warning Label Act of 2019. Dingell and Cicilline amendments to H.R. 2500, National Defense Authorization Act, regarding PFAS CERCLA designation (Dingell), and prohibiting the use of forced arbitration in SCRA claims (Cicilline). H.R. 5216/ S. 2943, Quality Care for Nursing Home Residents Act of 2019. H.R. 5326, Fairness in Nursing Home Arbitration Act. H.R. 4544, Ensuring Fair Legal Recourse for Private Student Loan Borrowers Act. H.R. 5279, Cosmetic Safety Enhancement Act of 2019. H.R. 5017, Natural Cosmetics Act. H.R. 535, PFAS Action of 2019. S. 2838, A bill to amend the Ted Stevens Olympic Amateur Sports Act to improve transparency of the United States Center for Safe Sport, to provide grant accountability, and to protect victims of abuse from retaliation, and for other purposes. H.R. 4982, Health Care Workforce Protection Act of 2019. S. 3372, Health Care Workforce Protection Act. H.R. 748, CARES Act, with specific regard to immunity provisions. S. 3548, CARES Act, with specific regard to immunity provisions. H.R. 6201, Families First Coronavirus Response Act, with specific regard to immunity provisions. H.R. 6379, Take Responsibility for Workers and Families Act, with specific regard to immunity provisions. H.R. 6101/ S. 3400, Ending Passenger Rail Forced Arbitration. H.R. 6058, SHOP SAFE Act of 2020. H.R. 6044, Accurate Labels Act. Draft legislation regarding additions to the PREP Act. General lobbying with regard to asbestos in talc and related liability issues. General lobbying with regard to asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to preemption of state causes of action. General lobbying with regard to PFAS liability issues. General lobbying with regard to evidence availability in pipeline safety legislation. General lobbying with regard to immunity provisions in COVID-19 legislation.
Client expense: $1,370,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
2020 · first_quarter · Torts
H.R. 1603: The Alan Reinstein Ban Asbestos Now Act of 2019 H.R. 4296: The "Safe Cosmetics and Personal Care Products Act of 2019" H.R. 5279: Cosmetic Safety Enhancement Act of 2019 S. 766: The PROTECT Asbestos Victims Act of 2019
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Torts
H.R. 1603: The Alan Reinstein Ban Asbestos Now Act of 2019 H.R. 4296: The "Safe Cosmetics and Personal Care Products Act of 2019" H.R. 5279: Cosmetic Safety Enhancement Act of 2019 S. 766: The PROTECT Asbestos Victims Act of 2019
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions
Client expense: $1,480,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · first_quarter · Manufacturing
H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain
Client expense: $165,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of
2020 · first_quarter · Chemicals/Chemical Industry
Uniformity in Consumer Product Ingredient Disclosure HR 4296 Safe Cosmetics and Personal Care Products Act of 2019 EPA Emerging Viral Pathogens Guidance for Antimicrobial Pesticides (COVID-19 Response) EPA Active and Inert Ingredient for Disinfectants Review (COVID-19 Response) EPA Alternate Raw Material Suppliers Review (COVID-19 Response) EPA Alternate Production Facilities Review (COVID-19 Response) EPA Expedited Date Review for Product Efficacy/Corona Virus (COVID-19 Response) EPA Regional Port Approval for Imported Finished Disinfectant Products (COVID-19 Response)
Client expense: $801,035 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Transportation, Dept of (DOT), U.S. Trade Representative (USTR), Vice President of the U.S.
2020 · first_quarter · Health Issues
HOUSE AND SENATE APPROPRIATIONS Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) CURRENT LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports reforming and strengthening the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; H.R. 5017 - Natural Cosmetics Act; and additional proposals that would impact the regulation of cosmetics and personal care products. Breast Cancer Prevention Partners visits Congressional offices to oppose H.R. 6044 - Accurate Labels Act, and other legislative proposals that seek to undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products. Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of pesticides and personal care products. These include H.R. 5986 - Environmental Justice for All Act and S.2236 - Environmental Justice Act of 2019. FUTURE LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A (BPA). Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS). Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions. Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural". REGULATION AND LEGISLATIVE INTENT: P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: $10,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · first_quarter · Consumer Issues/Safety/Products
HOUSE AND SENATE APPROPRIATIONS Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) CURRENT LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports reforming and strengthening the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; H.R. 5017 - Natural Cosmetics Act; and additional proposals that would impact the regulation of cosmetics and personal care products. Breast Cancer Prevention Partners visits Congressional offices to oppose H.R. 6044 - Accurate Labels Act, and other legislative proposals that seek to undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products. Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of pesticides and personal care products. These include H.R. 5986 - Environmental Justice for All Act and S.2236 - Environmental Justice Act of 2019. FUTURE LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A (BPA). Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS). Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions. Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural". REGULATION AND LEGISLATIVE INTENT: P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: $10,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · first_quarter · Chemicals/Chemical Industry
HOUSE AND SENATE APPROPRIATIONS Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) CURRENT LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports reforming and strengthening the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; H.R. 5017 - Natural Cosmetics Act; and additional proposals that would impact the regulation of cosmetics and personal care products. Breast Cancer Prevention Partners visits Congressional offices to oppose H.R. 6044 - Accurate Labels Act, and other legislative proposals that seek to undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products. Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of pesticides and personal care products. These include H.R. 5986 - Environmental Justice for All Act and S.2236 - Environmental Justice Act of 2019. FUTURE LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A (BPA). Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS). Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions. Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural". REGULATION AND LEGISLATIVE INTENT: P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: $10,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · first_quarter · Environment/Superfund
HOUSE AND SENATE APPROPRIATIONS Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) CURRENT LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports reforming and strengthening the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; H.R. 5017 - Natural Cosmetics Act; and additional proposals that would impact the regulation of cosmetics and personal care products. Breast Cancer Prevention Partners visits Congressional offices to oppose H.R. 6044 - Accurate Labels Act, and other legislative proposals that seek to undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products. Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of pesticides and personal care products. These include H.R. 5986 - Environmental Justice for All Act and S.2236 - Environmental Justice Act of 2019. FUTURE LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A (BPA). Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS). Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions. Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural". REGULATION AND LEGISLATIVE INTENT: P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: $10,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2020 · first_quarter · Consumer Issues/Safety/Products
H.R. 1816, Children's Product Warning Label Act of 2019; H.R. 5017, Natural Cosmetics Act; H.R. 5279, Cosmetic Safety Enhancement Act; H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019; H.R. 5141/S. 2886, Humane Cosmetics Act - Issues related to regulation of cosmetic animal testing; S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019; H.R. 6058, Stopping Harmful Offers on Platforms by Screening Against Fakes in E-commerce (SHOP SAFE) Act of 2020; Issues related to the ingredients in hand sanitizer and the availability of hand sanitizer; Issues related to the classification of personal care/hygiene manufacturers as essential places of business
Client expense: $500,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2019 · fourth_quarter · Consumer Issues/Safety/Products
We worked on H.R. 4296 the Safe Cosmetics and Personal Care Products Act to ensure that cosmetics and personal care products that targeted people of color were included in the bill. We also worked to make sure that funds were set aside to support research on the health effects of chemicals that are most regularly found in the cosmetic and personal care products targeting people of color.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2019 · fourth_quarter · Consumer Issues/Safety/Products
Cosmetics Regulation S. 726 Personal Care Products Safety Act Consumer protection and product safety standards and regulations in cosmetic industry H.R. 4296 - Safe Cosmetics and Personal Care Products Act of 2019
Client expense: Not reported · Firm income: $20,000
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Consumer Issues/Safety/Products
Monitoring FDA regulation of cosmetics and Consumer Product Safety issues. Monitor data breach notification, cyber-security and digital privacy proposals. H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 4296 - Safe Cosmetics and Personal Care Products Act of 2019. S. 726 - Personal Care Products Safety Act.
Client expense: Not reported · Firm income: $50,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2019 · fourth_quarter · Consumer Issues/Safety/Products
H.R. 1816, Children's Product Warning Label Act of 2019; H.R. 5017, Natural Cosmetics Act; H.R. 5279, Cosmetic Safety Enhancement Act; H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019 H.R. 5141/S. 2886, Humane Cosmetics Act - Issues related to regulation of cosmetic animal testing S. 2740/H.R. 3443, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 Combating Counterfeits draft legislation
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2019 · fourth_quarter · Consumer Issues/Safety/Products
H.R. 1423, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 610, Forced Arbitration Injustice Repeal Act (FAIR), which would eliminate forced arbitration in consumer and employment contracts. S. 608, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education. H.R. 1430, A bill to provide that chapter 1 of title 9 of the United States Code, relating to the enforcement of arbitration agreements, shall not apply to enrollment agreements made between students and certain institutions of higher education, and to prohibit limitations on the ability of students to pursue claims against certain institutions of higher education S. 630, Arbitration Fairness for Consumers Act, a bill to amend the Consumer Financial Protection Act of 2010 with respect to arbitration. H.R. 1443, Ending Forced Arbitration of Sexual Harassment act of 2019, bill to amend title 9 of the United States Code with respect to arbitration, prohibiting the use of forced arbitration in cases of sexual harassment, assault, discrimination. S. 635, A bill to restore statutory rights to the people of the United States from forced arbitration. S. 620, Safety Over Arbitration, a bill to amend title 9, United States Code, with respect to arbitration. S. 726, Personal Care Products Safety Act, to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 4296, Safe Cosmetics and Personal Care Products Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, specifically regarding preemption and immunity provisions. H.R. 2750, Justice for Servicemembers Act, prohibiting the use of forced arbitration against members of the armed forces. H.R. 2749/ S. 1491 Restoring Justice for Workers Act, prohibiting the use of forced arbitration in employment disputes. H.R. 3764, Justice for Student Borrowers Act, prohibiting the use of forced arbitration in student loan agreements. S. 766 PROTECT Asbestos Victims Act of 2019. H.R. 1603/ S. 717 Alan Reinstein Ban Asbestos Now Act of 2019. H.R. 1816, Children's Product Warning Label Act of 2019. Dingell and Cicilline amendments to H.R. 2500, National Defense Authorization Act, regarding PFAS CERCLA designation (Dingell), and prohibiting the use of forced arbitration in SCRA claims (Cicilline). H.R. 5216/ S. 2943 Quality Care for Nursing Home Residents Act of 2019. H.R. 5326 Fairness in Nursing Home Arbitration Act. H.R. 4544 Ensuring Fair Legal Recourse for Private Student Loan Borrowers Act. H.R. 5279 Cosmetic Safety Enhancement Act of 2019. H.R. 5017 Natural Cosmetics Act. H.R. 535 PFAS Action of 2019. S. 2838, A bill to amend the Ted Stevens Olympic Amateur Sports Act to improve transparency of the United States Center for Safe Sport, to provide grant accountability, and to protect victims of abuse from retaliation, and for other purposes. H.R.4982 - Health Care Workforce Protection Act of 2019. Draft legislation regarding additions to the PREP Act. Draft legislation regarding the Accurate Labels Act. General lobbying with regard to asbestos in talc and related liability issues. General lobbying with regard to Asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to preemption of state causes of action. General lobbying with regard to PFAS liability issues. General lobbying with regard to evidence availability in pipeline safety legislation.
Client expense: $1,300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
2019 · fourth_quarter · Health Issues
HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) CURRENT LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296, the Safe Cosmetics and Personal Care Products Act of 2019, S.726, the Personal Care Products Safety Act, and any other legislation that would impact the regulation of personal care products. FUTURE LEGISLATIVE PROPOSALS: Breast Cancer Prevention Partners visits Congressional offices to oppose legislative proposals that undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products. Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of pesticides and personal care products. Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A (BPA). Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS). Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions. Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural". REGULATION AND LEGISLATIVE INTENT: P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: $10,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE